SNS Insider Reports Steady Growth in the Parkinson’s Disease Treatment Market, Expanding from $5.37 Billion in 2023 to $8.75 Billion by 2032, Supported by Aging Populations, Breakthrough Neurotherapeutics, and Improved Access to Specialty Care.
Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) — Parkinson’s Disease Treatment Market Size & Growth Outlook
According to SNS Insider, the global Parkinson’s Disease Treatment Market was valued at $5.37 billion in 2023 and is projected to reach $8.75 billion by 2032, reflecting a CAGR of 5.57% during 2024 to 2032.
The market is strengthened by a rising number of diagnosed cases, expanded use of advanced treatments such as deep brain stimulation and gene therapy, and ongoing improvements in healthcare infrastructure worldwide.
Get Free Sample Report of the Parkinson’s Disease Treatment Market: https://www.snsinsider.com/sample-request/4532
Market Overview
Parkinson’s disease is one of the fastest-growing neurological disorders in the world, and the rising prevalence is accelerating demand for effective therapies. Traditional medications such as levodopa continue to serve as primary treatment options for millions of patients. In the United States alone, approximately 1 million individuals rely on levodopa, and nearly 70 percent of all patients receive the therapy at some point during their clinical journey.
Alongside conventional therapy, advanced interventions such as deep brain stimulation (DBS) are becoming more accessible. In 2023, more than 25,000 DBS procedures were performed across over 150 specialized centers in the United States. The procedure is typically recommended for individuals with severe motor symptoms that are no longer adequately managed by medication. DBS has shown strong potential for restoring motor control and improving overall quality of life.
While the treatment landscape continues to expand, high therapy costs and the chronic nature of the disease remain hurdles. Nonetheless, ongoing research, expanded coverage options, and new clinical programs are improving long-term patient outcomes.
Key Parkinson’s Treatment Companies Profiled in the Report
- AbbVie
- Johnson and Johnson
- Novartis
- Teva Pharmaceutical Industries
- UCB Pharma
- Prevail Therapeutics (Eli Lilly)
- Voyager Therapeutics
- Inflazome
- Denali Therapeutics
- Other Leading Companies
Segmentation Analysis:
By Drug Class
Carbidopa-levodopa held a market share of over 30% in 2023 as combined treatment is the most efficient and commonly recommended for controlling symptoms of Parkinson’s disease. Dopamine Agonists are experiencing the quickest growth rate during the forecast period within the Parkinson’s disease treatment market as these medications imitate dopamine’s effects in the brain, assisting in controlling motor symptoms and potentially postponing the necessity for Carbidopa-Levodopa treatment
By Sales Channel
The retail sector held a major market share of 61% in 2023 and dominated the market due its widespread coverage and convenience. The hospital sector is accounted to have a faster CAGR during 2024-2032. Hospitals offer specialized treatment, such as advanced procedures and surgical actions, which are generally not offered in retail environments.
Need Any Customization Research on Parkinson’s Disease Treatment Market, Enquire Now: https://www.snsinsider.com/enquiry/4532
Regional Insights:
North America dominated in 2023 with a 39% market share, due to its top-notch healthcare facilities, substantial R&D investments, and strong awareness regarding neurological conditions.
The Asia Pacific region is to experience the most rapid growth rate during the forecast period 2024-2032, mainly as a result of higher healthcare spending and growing recognition of neurological conditions.
Recent Developments:
- In March 2023, Stimwave Technologies introduced new non-invasive neuromodulation therapy for Parkinson’s Disease. The therapy allows for controlling the symptoms of the disease such as tremors, rigidity, etc. through targeted stimulation.
- In September 2022, BrainStorm Cell Therapeutics introduced Nurown, a cell-based therapy for Parkinson’s Disease. The proposed therapy includes the implantation of modified stem cells for neural repair.
Exclusive Sections of the Report (The USPs):
- PARKINSON’S INCIDENCE & PREVALENCE METRICS – helps you understand disease burden trends across demographics and regions, enabling better forecasting of treatment demand.
- HOSPITAL TREATMENT TRENDS INDEX (BY REGION) – helps you identify regional disparities in diagnosis rates, treatment accessibility, hospital admissions, and care pathways.
- DRUG PRODUCTION & USAGE VOLUME ANALYSIS – helps you evaluate the manufacturing capacity, consumption patterns, and supply-demand balance for key Parkinson’s disease drugs.
- HEALTHCARE SPENDING DISTRIBUTION SCORE – helps you assess how government, commercial insurers, private payers, and out-of-pocket expenditure shape treatment affordability and market expansion.
- PATIENT CARE BURDEN & RESOURCE UTILIZATION METRICS – helps you understand hospitalization duration, therapy intensity, outpatient follow-ups, and overall care resource consumption impacting treatment economics.
Purchase Single User PDF of Parkinson’s Disease Treatment Market Report: https://www.snsinsider.com/checkout/4532
Parkinson’s Disease Treatment Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | $5.37 Billion |
| Market Size by 2032 | $8.75 Billion |
| CAGR | CAGR of 5.57% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Segments | • By Drug Class (Carbidopa-Levodopa, Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics, Others) • By Sales Channel (Hospital, Retail, Online) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Related Reports
Alzheimer’s Therapeutics Market
Multiple Sclerosis (MS) Market
Epilepsy Drugs Market
Deep Brain Stimulation (DBS) Devices Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com